
Concern over weight gain after ‘skinny jabs'
The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain.
The guidance is for people who are offered the treatments through the NHS.
An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment.
Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years.
The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed.
It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'.
This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients.
'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice.
'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made.
'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.'
Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix.
Little swaps can make tasty, healthy changes.
For lots of tips and support to eat better visit: https://t.co/T56V7G8FkJ pic.twitter.com/K42yzvkF2V
— NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025
'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits.
'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support.
'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term.
'This standard ensures healthcare services are equipped to provide that essential ongoing support.'
Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight.
'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable.
'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.'
Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk.
'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice.
'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
21 minutes ago
- The Independent
What is RSV? The main cause of hospital admissions for children
Health experts say the UK should brace for a surge in a potentially serious virus following a record number of cases in Australia. NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. In Australia, respiratory syncytial virus (RSV) cases have surged in recent months, and officials have said that cases have been steadily increasing in England since the start of 2025. NHS England has urged pregnant women to get the vaccine, which protects against RSV, in order to protect their newborn babies. The virus is a leading cause of death among babies and the main cause of hospital admissions for children. Kate Brintworth, chief midwifery officer for NHS England, said that while for most adults, RSV 'only causes mild, cold-like symptoms, for older adults and young children, it can lead to serious breathing problems that can end up in hospitalisation'. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab, and NHS England will start inviting people to come forward in the next few weeks. Symptoms of an RSV infection NHS RSV is a common cause of coughs and colds, but some people have a high risk of getting seriously ill from the virus, including babies and adults over the age of 75. In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency published data showing the efficacy of the vaccine. It said that the jab for pregnant women can prevent 72 per cent of hospital admissions for their babies. And the vaccine is 82 per cent effective at preventing hospital admissions for RSV among older adults, UKHSA said.


Glasgow Times
an hour ago
- Glasgow Times
Respiratory Syncytial Virus: UK warning over rise in cases
Respiratory Syncytial Virus (RSV) is a common cause of coughs and colds, with most children getting an RSV infection at least once before they turn two years old. However, it can cause "serious breathing problems", and following a record number of RSV cases in Australia, the UK is being warned over a similar rise here. NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. What is Respiratory Syncytial Virus? Respiratory Syncytial Virus (RSV) infections are described as "very common" by the NHS , but can cause serious illness in the elderly and young children. Despite typically being unserious, some babies and adults have a higher risk of getting seriously ill from RSV. The virus is a common cause of a type of chest infection called bronchiolitis in babies, which can cause breathing problems and may need to be treated in hospital. There is a vaccine for RSV, which, as the NHS explains, is recommended if: You're pregnant (from 28 weeks of pregnancy) – this will help protect your baby for the first few months after they're born You're aged 75 to 79 Last week, the UK Health Security Agency published data showing the efficacy of the vaccine. It was revealed that the jab for pregnant women can prevent 72% of hospital admissions for their babies. Meanwhile, the UKHSA said the vaccine is 82% effective at preventing hospital admissions for RSV among older adults. Symptoms of an RSV infection The NHS says symptoms of an RSV infection typically start within a few days of getting infected. Most people only get cold-like symptoms, such as: a runny or blocked nose a cough sneezing tiredness a high temperature – signs include your back or chest feeling hotter than usual, sweatiness and shivering (chills) It says that babies with RSV may also be irritable and feed less than usual. What is RSV? 💭 It's a respiratory virus that can cause serious illness in the elderly & young children. If a woman has the vaccination during pregnancy, it cuts the risk of serious lung infection caused by #RSV in her baby's first 6 months Read more: — UK Health Security Agency (@UKHSA) August 4, 2025 However, if the virus leads to a more serious infection (such as pneumonia or bronchiolitis), it may also cause: a cough that gets worse shortness of breath faster breathing or long gaps between breaths difficulty feeding (in babies) or loss of appetite noisy breathing (wheezing) confusion (in older adults) Warning to UK over rise in RSV cases Health experts have warned that the UK should brace for a surge in RSV following a record number of cases in Australia. Officials have said that cases have been steadily increasing in England since the start of 2025, and NHS England has urged pregnant women to get the vaccine to protect newborn babies. It said that the virus is a leading cause of death among babies and the main cause of hospital admissions for children. Kate Brintworth, chief midwifery officer for NHS England, said: 'While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Recommended reading: Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab. NHS England will start inviting people to come forward in the next few weeks.


Daily Record
an hour ago
- Daily Record
NHS warns serious virus 'rampant in Australia' is coming to UK as cases surge
The NHS has warned that people should be on the lookout for a serious virus with the most vulnerable getting vaccinations Britain should prepare for a spike in a potentially dangerous virus after Australia recorded unprecedented case numbers, health experts have warned. NHS bosses said that Australia's winter season often serves as a reliable indicator of how viruses will behave in England. Following a dramatic rise in respiratory syncytial virus (RSV) infections across Australia, officials have confirmed that case numbers have been climbing steadily in England since early 2025. NHS England has called on expectant mothers to receive the RSV jab to shield their newborn infants from the illness. Health chiefs said the virus ranks as a top killer of babies and represents the primary reason children end up in hospital. Kate Brintworth, chief midwifery officer for NHS England, said: "While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." Expectant mothers can receive the vaccination from 28 weeks into their pregnancy via maternity services or their local GP practice. Adults aged between 75 and 79 also qualify for the injection, with NHS England set to begin sending out invitations over the coming weeks. RSV is a frequent culprit behind coughs and colds. However, certain individuals, such as infants and those over 75, are at a heightened risk of severe illness from the virus. In babies, RSV often leads to a chest infection known as bronchiolitis. The UK Health Security Agency recently released data demonstrating the vaccine's effectiveness. According to their findings, the jab for expectant mothers can prevent 72% of hospital admissions for their newborns. Furthermore, the vaccine is 82% effective in preventing hospital admissions due to RSV among the elderly, as per the UKHSA.